Stacy Mandras, MD

CF-Cardiologist-Transplant

Heart, Lung and Vascular Research

Expertise of Stacy Mandras, MD

Biography: Dr. Stacy Mandras is board certified in cardiovascular disease, advanced heart failure and transplant cardiology. She also serves as the Medical Director of Pulmonary Hypertension. She joined AdventHealth in 2020 from New Orleans, where she served as the Director of Pulmonary Hypertension and the Program Director for the Advanced Heart Failure and Transplant Cardiology Fellowship at Ochsner Medical Center. A Phi Beta Kappa honors graduate of the University of Maryland (UM) and the University of Maryland School of Medicine, Dr. Mandras also carried out her internal medicine residency at UM before undertaking consecutive fellowships in cardiovascular medicine and in heart failure and transplant cardiology at Washington University-Barnes-Jewish Hospital in St. Louis, MO. She is proficient in English and Spanish.
Education: University of Maryland School of Medicine
Residency: Internal Medicine at University of Maryland
Fellowship: Cardiovascular Disease at Washington University & Barnes Hospital
Board Certifications: American Board of Internal Medicine

Publications

Obesity and Weight Loss Strategies for Patients With Heart Failure

2024, JACC-HEART FAILURE
Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension

2023, CURRENT OPINION IN CARDIOLOGY
Elusive Diagnosis of Eosinophilic Myocarditis: A Case Series

2021, CURRENT PROBLEMS IN CARDIOLOGY

More sources loaded
Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 mu g (nine breaths) four times daily

2021, PULMONARY CIRCULATION
Ruptured hemorrhagic bulla in a patient with a HeartMate 3 treated with an Amplatzer device

2021, ARCHIVOS DE CARDIOLOGIA DE MEXICO
Rabbit Antithymocyte Globulin Induction in Heart Transplant Recipients at High Risk for Rejection

2021, OCHSNER JOURNAL
Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways

2021, JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Sarcoidosis-Associated Pulmonary Hypertension: An Updated Review and Discussion of the Clinical Conundrum

2021, CURRENT PROBLEMS IN CARDIOLOGY
Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis- Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis

2021, CURRENT PROBLEMS IN CARDIOLOGY
Bariatric Surgery in Patients with Obesity and Ventricular Assist Devices Considered for Heart Transplantation: Systematic Review and Individual Participant Data Meta-analysis

2021, JOURNAL OF CARDIAC FAILURE

Associated Clinical Trials for Stacy Mandras, MD

NCT03683186

ADVANCE OUTCOMES - A Study Evaluating the Efficacy and Safety of Ralinepag To Improve Treatment Outcomes in PAH Patients

This study is currently enrolling.

Research Area: Heart, Lung and Vascular Research

Research Location: Orlando, Florida

A research study is a scientific way to improve or develop new methods of health care. Studies are designed to answer specific questions on how to prevent, diagnose, or treat diseases and disorders...
NCT06616974

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

This study is not currently enrolling.

Research Area: Heart, Lung and Vascular Research

The study Sponsor is developing the investigational (experimental) drug TX000045 as a potential new treatment for patients with high lung blood pressure due to heart failure.
NCT03683186

ADVANCE EXTENSION - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-Label Extension

This study is not currently enrolling.

Research Area: Heart, Lung and Vascular Research

If you have taken part in a research study with ralinepag, the investigational study drug, you may be able to take part in this extension study. This means that all participants will receive the...

More clinical trials loaded
NCT04945460

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

This study is not currently enrolling.

Associated Conditions: Pulmonary Hypertension

Research Area: Heart, Lung and Vascular Research

Research Location: Orlando, Florida

You are being asked to take part in a research study of an experimental treatment called
sotatercept. “Experimental” means that sotatercept is currently being tested and is not
approved for sale by...

Stacy Mandras, MD

Expertise of Stacy Mandras, MD

Associated Clinical Trials for Stacy Mandras, MD

ADVANCE OUTCOMES - A Study Evaluating the Efficacy and Safety of Ralinepag To Improve Treatment Outcomes in PAH Patients

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

ADVANCE EXTENSION - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-Label Extension

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)